Positive Results

 
News Articles for Positive Results top ^
Exelixis Inc. (NASDAQ:EXEL) today announced the positive results from coBRIM, the phase 3 pivotal trial conducted by Exelixis’ collaborator Genentech, a member of the Roche Group, evaluating cobimetinib, a specific MEK inhibitor discovered by Exelixis, in combination with vemurafenib in previously untreated patients with unresectable locally advanced or metastatic melanoma harboring a BRAF V600 mutation.
Sign-up for Exelixis Announces Positive Results from Phase 3 Pivotal Trial of Cobimetinib in Combination with Vemurafenib in Patients with BRAF V600 Mutation-Positive Advanced Melanoma investment picks
http://at.marketwire.com/accesstracking/AccessTrackingLogServlet?docid=0967927001&sourceType=1 http://media3.marketwire.com/logos/20130517-TERANGA%20BIG.jpg TORONTO, ONTARIO --
Sign-up for Teranga Gold Confirms 2014 Production Guidance and Announces Positive Results on Key Growth Initiatives investment picks
Strongly Positive Results, Presented at European Society for Medical Oncology (ESMO) 2014 Congress, Demonstrated Oncotype DX® Prostate Cancer Test was an Independent Predictor of Tumor Aggressiveness Study, Including 20% African-American Men, Confirmed Similar Predictive Outcomes Regardless of Race REDWOOD CITY, Calif.
Sign-up for Genomic Health Announces Positive Results from Latest Clinical Validation Study of Oncotype DX® as Predictor of Near- and Long-term Outcomes in Racially Diverse Group of Prostate Cancer Patients investment picks
2014/11/7
Cardiome Announces Positive Results from the BRINAVESS® Asia-Pacific Phase 3 Clinical Trial Canada NewsWire NASDAQ: CRME TSX: COM VANCOUVER , Nov.
Sign-up for Cardiome Announces Positive Results from the BRINAVESS® Asia-Pacific Phase 3 Clinical Trial investment picks
2014/9/16
Achieved Primary 30 Day Endpoint Patients in CARENET Trial had significantly lower incidence of new ischemic lesions compared to historical control groups of non-mesh covered carotid stents BOSTON , Sept.
Sign-up for InspireMD Announces Positive Results from CGuard™ CARENET Trial with 0% MACE reported at 30 Days investment picks
Regulatory News: Ipsen (Euronext: IPN; ADR: IPSEY) today announced positive results from the phase III study of triptorelin pamoate 11.25 mg (Decapeptyl ® 3 months) administered subcutaneously in patients with locally advanced or metastatic prostate cancer at the European Association of Urology (EAU) 14 th Central European Meeting in Cracow, Poland (10-12 October 2014). The primary objective of the study was to assess the efficacy and safety profile of the sustained-release triptorelin pamoate 11.25 mg (Decapeptyl ® 3 months) formulation when administered by the subcutaneous route in men with locally advanced or metastatic prostate cancer.
Sign-up for Ipsen Announces Positive Results from Phase III Clinical Study of Decapeptyl® (triptorelin pamoate) 11.25 mg Administered by Subcutaneous Route to Prostate Cancer Patients investment picks
Additional Data Acceptances Include Multiple Oncotype DX® Studies in Breast and Renal Cancers REDWOOD CITY, Calif.
Sign-up for Genomic Health Announces Presentation of Positive Results from Latest Prostate Cancer Clinical Validation Study at the European Society for Medical Oncology (ESMO) 2014 Congress investment picks
- Alirocumab, an investigational treatment for hypercholesterolemia, showed a 62 percent reduction in LDL-C compared to placebo at 24 weeks on top of maximally-tolerated lipid-lowering therapy in ODYSSEY LONG TERM trial - PARIS and TARRYTOWN, N.Y. , Aug.
Sign-up for Sanofi and Regeneron Announce Presentation of Detailed Positive Results from Four Pivotal Alirocumab Trials at ESC Congress 2014 investment picks
Alirocumab, an investigational treatment for hypercholesterolemia, showed a 62 percent reduction in LDL-C compared to placebo at 24 weeks on top of maximally-tolerated lipid-lowering therapy in the ODYSSEY LONG TERM trial TARRYTOWN, New York and PARIS , Aug.
Sign-up for Regeneron and Sanofi Announce Presentation of Detailed Positive Results from Four Pivotal Alirocumab Trials at ESC Congress 2014 investment picks
-- Primary endpoint was met for 50 mg twice daily dosing --
Sign-up for Ardelyx Reports Positive Results from Its Phase 2b Clinical Trial Evaluating Tenapanor in IBS-C Patients investment picks
Teva Pharmaceutical Industries Ltd., (NYSE:TEVA) today announced the initiation of a rolling New Drug Application (NDA) submission to the U.S. Food and Drug Administration for hydrocodone bitartrate extended-release tablets designed with Teva’s proprietary technology providing potential abuse-deterrent properties (CEP-33237) as allowed for fast track designated products.
Sign-up for Teva Announces Initiation of New Drug Application and Positive Results from Second Human Abuse Liability Study for CEP-33237 (Hydrocodone Bitartrate) Extended-Release Tablets investment picks
Phase 1 Clinical Trial Highlights: SANTA MONICA, Calif., Oct.
Sign-up for Kite Pharma Announces Patients With Relapsed or Refractory Acute Lymphoblastic Leukemia (ALL) Experience Positive Results After Receiving Anti-CD19 Chimeric Antigen Receptor (CAR) T Cells investment picks
http://media.marketwire.com/attachments/201408/268735_TheravanceBiopharmaLogo.jpg http://at.marketwire.com/accesstracking/AccessTrackingLogServlet?PrId=1155895&ProfileId=051205&sourceType=1 SOUTH SAN FRANCISCO, CA --
Sign-up for Theravance Biopharma Announces Positive Results From Phase 1 Proof-of-Concept Study of TD-6450, an NS5A Inhibitor to Treat Hepatitis C investment picks
2014/10/29
Trial meets primary endpoint with I.V. CR845 showing highly statistically significant reductions (p <0.0001) in scores for "drug liking," as well as "feeling high", "overall liking", and "take drug again" when compared to I.V. pentazocine, a Schedule IV opioid analgesic Results suggest potential for I.V. CR845 to be first Schedule V or non-scheduled peripheral opioid for acute pain Conference Call/Webcast at 9:00 a.m. ET today SHELTON, Conn., Oct.
Sign-up for Cara Therapeutics Announces Positive Results From Human Abuse Liability Trial of Peripheral Opioid for Acute Pain, I.V. CR845 investment picks
Phase 1-2a Clinical Trial Highlights: SANTA MONICA, Calif., Aug.
Sign-up for Kite Pharma Announces Patients With Aggressive Non-Hodgkin's Lymphoma Experience Positive Results After Receiving Anti-CD19 Chimeric Antigen Receptor (CAR) T Cells at the National Cancer Institute (NCI) investment picks
2014/8/19
http://at.marketwire.com/accesstracking/AccessTrackingLogServlet?PrId=11G020224-001&sourceType=1 http://www.marketwire.com/library/MwGo/2014/8/19/11G020224/Vivakor_logo-191968837290-787324512543.jpg IRVINE, CA--(Marketwired - August 19, 2014) - Vivakor Inc. (PINKSHEETS: VIVK) announced GAAP based financial results for the quarter ended June 30, 2014.
Sign-up for Vivakor Announces Solid 2nd Quarter 2014 Results and 5th Successive Quarter of Positive Results investment picks

Premium Membership: Features and Benefits
Wide-Moat Screener for Stocks

Put a moat around your portfolio. Sniff out the most promising opportunities that can ride through any market.

Gold Medalist Screener for Funds

Narrow the available universe of 5000 funds to the top rated gold and silver. Then, sort for manager tenure, expense ratio, risk and return to create your own index-beating fund watchlist.

Thousands of Premium Analyst Reports

While many of our competitors measure a stock's worth with a computer program, Morningstar's staff of 150+ analyst sift through company fillings, financial data and a wealth of other sources to deliver an unvarnished review of any investment. In fact, twelve Morningstar analysts have been recognized by WSJ as "Best on the Street" in the US.

Premium Portfolio Monitor

Make decisions with confidence. Load your investments into our research center and automatically connect to all our proprietary tools and data points.

Mobile

Never be without critical research. Free with your active membership, take our Premium data and guidance wherever you go with Morningstar for iPad®, iPhone®, and Android apps.

Morningstar's Guarantee

We're looking out for you. If after your 14-day free trial, you find that a Morningstar Premium membership is not for you, cancel any time and we'll be happy to refund the unused portion - no questions asked.

Go Premium!
Exclusive Premium Member Benefits
Get the best thinking of 150+ disciplined
objective, experienced analysts-dedicated to
specific industries and securities.
+2,500 Analyst Reports
Wide Moat Screener for Stocks
Medalist Screener for Funds
Premium Portfolio Manager with X-Ray & Monitor
Premium eNewsletters
Morningstar Basic Benefits (All)
Sign up now - No charge for the first 14 days
Positive Results
Name |  Ticker |  Star Rating |  Market Cap |  Stock Type |  Sector |  Industry Star Rating |  Investment Style |  Total Assets |  Category |  Top Holdings |  Top Sectors |  Symbol |  Title Star Rating |  Category |  Total Assets |  Top Holdings |  Top Sectors |  Symbol |  Name Title |  Date |  Author |  Collection |  Interest |  Popularity Name |  Ticker |  Star Rating |  Market Cap |  Stock Type |  Sector |  Industry Star Rating |  Investment Style |  Total Assets |  Category |  Top Holdings |  Top Sectors |  Symbol / Ticker |  Title Star Rating |  Category |  Total Assets |  Symbol / Ticker |  Name Title |  Date |  Author |  Collection |  Popularity |  Interest Title |  Date |  Company |  Symbol |  Interest |  Popularity Title |  Date |  Company |  Symbol |  Interest |  Popularity Topic |  Sector |  Key Indicators |  User Interest |  Market Cap |  Industry Name |  Ticker |  Popularity |  Our Choices |  Most Recent Topic |  Sector |  Key Indicators |  User Interest |  Market Cap |  Industry |  Topic |  Sector |  Key Indicators |  User Interest |  Market Cap |  Industry

Previous: Portfolio Update  |  Next: Positive Trends